Literature DB >> 10189716

The selection of intracellular antibodies.

A Cattaneo1, S Biocca.   

Abstract

The intracellular expression of antibodies in mammalian cells is a strategy to inhibit the in vivo function of selected molecules but is limited by the unpredictable behaviour of antibodies when intracellularly expressed. Recent advances in the field of antibody expression in Escherichia coli show that the introduction of mutations can improve the properties of some antibody domains, but the general applicability of this approach to intracellular antibodies remains to be proved. As a complement to rational approaches, we describe selection schemes in which antibodies are selected on the basis of their performance in vivo as intracellular antibodies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10189716     DOI: 10.1016/s0167-7799(98)01268-2

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  29 in total

1.  Intrabody construction and expression III: engineering hyperstable V(H) domains.

Authors:  P Wirtz; B Steipe
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Role of native-state topology in the stabilization of intracellular antibodies.

Authors:  G Settanni; A Cattaneo; A Maritan
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

3.  Peptide-mediated broad-spectrum plant resistance to tospoviruses.

Authors:  Christoph Rudolph; Peter H Schreier; Joachim F Uhrig
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

Review 4.  Potential applications of intracellular antibodies (intrabodies) in stem cell therapeutics.

Authors:  Boon Chin Heng; David Michael Kemeny; Hua Liu; Tong Cao
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

5.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 6.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

7.  Optimizing recombinant antibodies for intracellular function using hitchhiker-mediated survival selection.

Authors:  Dujduan Waraho-Zhmayev; Bunyarit Meksiriporn; Alyse D Portnoff; Matthew P DeLisa
Journal:  Protein Eng Des Sel       Date:  2014-09-14       Impact factor: 1.650

8.  Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Authors:  Erik Kvam; Michael R Sierks; Charles B Shoemaker; Anne Messer
Journal:  Protein Eng Des Sel       Date:  2010-04-08       Impact factor: 1.650

9.  Engineering antibody fragments to fold in the absence of disulfide bonds.

Authors:  Min Jeong Seo; Ki Jun Jeong; Clinton E Leysath; Andrew D Ellington; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

10.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.